AR and prostate cancer: The stronger inhibition of AR signaling through ARSi in recent years has led to an increase of metastatic prostate cancers that de-differentiate into AR-negative disease and consequentially no longer respond to the inhibition of the AR signaling axis (Fig. 1a).